Go to Home

Search

-Advanced Search   -Search Guidelines

J Gynecol Oncol.  2010 Sep;21(3):137-150. 10.3802/jgo.2010.21.3.137.

Asian society of gynecologic oncology workshop 2010

Affiliations
  • 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. ksboo308@gmail.com
  • 2Department of Obstetrics and Gynecology, University of Indonesia, Jakarta, Indonesia.
  • 3Department of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India.
  • 4Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, Hong Kong.
  • 5Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • 6Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Seoul, Korea.
  • 7Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
  • 8Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
  • 9National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
  • 10Department of Obstetrics and Gynecology, Kyungpook National University, Daegu, Korea.
  • 11Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 12Department of Obstetrics and Gynecology, Women's Cancer Clinic, Yonsei University College of Medicine, Seoul, Korea.
  • 13Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taiwan, Mackay Medicine, Nursing and Management College, Taipei Medical University, Taipei, Taiwan.
  • 14Department of Obstetrics and Gynecology, Seoul National University Boramae Hospital, Seoul, Korea.
  • 15Department of Obstetrics and Gynecology, Kurume University, Kurume, Japan.
  • 16Department of Clinical Pharmacology, Seoul National University College of Medicine, Korea National Enterprise for Clinical Trials (KoNECT), Seoul, Korea.
  • 17Department of Gynecologic Oncology, KK Women's and Children's Hospital, Singapore.
  • 18Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • 19Uterine Cancer Branch, National Cancer Center, Goyang, Korea.
  • 20Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Abstract

This workshop was held on July 31-August 1, 2010 and was organized to promote the academic environment and to enhance the communication among Asian countries prior to the 2nd biennial meeting of Australian Society of Gynaecologic Oncologists (ASGO), which will be held on November 3-5, 2011. We summarized the whole contents presented at the workshop. Regarding cervical cancer screening in Asia, particularly in low resource settings, and an update on human papillomavirus (HPV) vaccination was described for prevention and radical surgery overview, fertility sparing and less radical surgery, nerve sparing radical surgery and primary chemoradiotherapy in locally advanced cervical cancer, were discussed for management. As to surgical techniques, nerve sparing radical hysterectomy, optimal staging in early ovarian cancer, laparoscopic radical hysterectomy, one-port surgery and robotic surgery were introduced. After three topics of endometrial cancer, laparoscopic surgery versus open surgery, role of lymphadenectomy and fertility sparing treatment, there was a special additional time for clinical trials in Asia. Finally, chemotherapy including neo-adjuvant chemotherapy, optimal surgical management, and the basis of targeted therapy in ovarian cancer were presented.

Keyword

ASGO; Workshop; Cervical caner; Endometrial cancer; Ovarian cancer; Clinical trials

MeSH Terms

Asia
Asian Continental Ancestry Group
Chemoradiotherapy
Endometrial Neoplasms
Female
Fertility
Humans
Hysterectomy
Laparoscopy
Lymph Node Excision
Mass Screening
Ovarian Neoplasms
Uterine Cervical Neoplasms
Vaccination

Reference

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. Epub 2010 Jun 17. DOI: 10.1002/ijc.25516.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001. 2:533–543.
4. Singh V, Sehgal A, Luthra UK. Screening for cervical cancer by direct inspection. BMJ. 1992. 304:534–535.
5. Nene BM, Deshpande S, Jayant K, Budukh AM, Dale PS, Deshpande DA, et al. Early detection of cervical cancer by visual inspection: a population-based study in rural India. Int J Cancer. 1996. 68:770–773.
6. Wesley R, Sankaranarayanan R, Mathew B, Chandralekha B, Aysha Beegum A, Amma NS, et al. Evaluation of visual inspection as a screening test for cervical cancer. Br J Cancer. 1997. 75:436–440.
7. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet. 1999. 353:869–873.
8. Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL, Elson P. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol. 2001. 98:441–444.
9. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA. 2005. 294:2173–2181.
10. Schiffman M, Castle PE. When to test women for human papillomavirus. BMJ. 2006. 332:61–62.
11. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000. 283:87–93.
12. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009. 19:1166–1176.
13. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007. 369:2161–2170.
14. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009. 374:1975–1985.
15. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009. 5:705–719.
16. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009. 199:926–935.
17. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009. 373:1949–1957.
18. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007. 196:1438–1446.
19. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007. 7:453–459.
20. Sharma R, Bailey J, Anderson R, Murdoch J. Laparoscopically assisted radical vaginal hysterectomy (Coelio-Schauta): a comparison with open Wertheim/Meigs hysterectomy. Int J Gynecol Cancer. 2006. 16:1927–1932.
21. Hopkins MP, Schnettler W. Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol. 2007. 107:2–3.
22. Fujii S, Takakura K, Matsumura N, Higuchi T, Yura S, Mandai M, et al. Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol. 2007. 107:4–13.
23. Dargent D. Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer. Am J Obstet Gynecol. 2002. 187:1728.
24. Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol. 2005. 98:3–10.
25. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH. Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer. BJOG. 2010. 117:340–347.
26. Olawaiye A, Del Carmen M, Tambouret R, Goodman A, Fuller A, Duska LR. Abdominal radical trachelectomy: success and pitfalls in a general gynecologic oncology practice. Gynecol Oncol. 2009. 112:506–510.
27. Abu-Rustum NR, Neubauer N, Sonoda Y, Park KJ, Gemignani M, Alektiar KM, et al. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol. 2008. 111:261–264.
28. Maneo A, Chiari S, Bonazzi C, Mangioni C. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol. 2008. 111:438–443.
29. Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecol Oncol. 2002. 84:145–149.
30. Milliken DA, Shepherd JH. Fertility preserving surgery for carcinoma of the cervix. Curr Opin Oncol. 2008. 20:575–580.
31. Wu J, Liu X, Hua K, Hu C, Chen X, Lu X. Effect of nerve-sparing radical hysterectomy on bladder function recovery and quality of life in patients with cervical carcinoma. Int J Gynecol Cancer. 2010. 20:905–909.
32. Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer. 1985. 55:9 Suppl. 2123–2130.
33. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999. 340:1137–1143.
34. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000. 18:1606–1613.
35. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999. 340:1144–1153.
36. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999. 17:1339–1348.
37. Ryu HS, Kang SB, Kim KT, Chang KH, Kim JW, Kim JH. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer. 2007. 17:132–136.
38. Fujii S. Anatomic identification of nerve-sparing radical hysterectomy: a step-by-step procedure. Gynecol Oncol. 2008. 111:Suppl 2. S33–S41.
39. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983. 250:3072–3076.
40. Camara O, Sehouli J. Controversies in the management of ovarian cancer: pros and cons for lymph node dissection in ovarian cancer. Anticancer Res. 2009. 29:2837–2843.
41. Tozzi R, Kohler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol. 2004. 93:199–203.
42. Park JY, Bae J, Lim MC, Lim SY, Seo SS, Kang S, et al. Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. Int J Gynecol Cancer. 2008. 18:1202–1209.
43. Zakashansky K, Bradley WH, Chuang L, Rahaman J, Dottino P. Recent advances in the surgical management of cervical cancer. Mt Sinai J Med. 2009. 76:567–576.
44. Mettler L, Meinhold-Heerlein I. The value of laparoscopic surgery to stage gynecological cancers: present and future. Minerva Ginecol. 2009. 61:319–337.
45. Chong GO, Park NY, Hong DG, Cho YL, Park IS, Lee YS. Learning curve of laparoscopic radical hysterectomy with pelvic and/or para-aortic lymphadenectomy in the early and locally advanced cervical cancer: comparison of the first 50 and second 50 cases. Int J Gynecol Cancer. 2009. 19:1459–1464.
46. Kim TJ, Lee YY, Kim MJ, Kim CJ, Kang H, Choi CH, et al. Single port access laparoscopic adnexal surgery. J Minim Invasive Gynecol. 2009. 16:612–615.
47. Lee YY, Kim TJ, Kim CJ, Park HS, Choi CH, Lee JW, et al. Single port access laparoscopic adnexal surgery versus conventional laparoscopic adnexal surgery: a comparison of peri-operative outcomes. Eur J Obstet Gynecol Reprod Biol. 2010. 151:181–184.
48. Fader AN, Escobar PF. Laparoendoscopic single-site surgery (LESS) in gynecologic oncology: technique and initial report. Gynecol Oncol. 2009. 114:157–161.
49. Chen CC, Falcone T. Robotic gynecologic surgery: past, present, and future. Clin Obstet Gynecol. 2009. 52:335–343.
50. Bedient CE, Magrina JF, Noble BN, Kho RM. Comparison of robotic and laparoscopic myomectomy. Am J Obstet Gynecol. 2009. 201:566.e1–566.e5.
51. Lonnerfors C, Persson J. Robot-assisted laparoscopic myomectomy: a feasible technique for removal of unfavorably localized myomas. Acta Obstet Gynecol Scand. 2009. 88:994–999.
52. Lee TS, Kim JW, Kim DY, Kim YT, Lee KH, Kim BG, et al. Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion. J Korean Med Sci. 2010. 25:552–556.
53. Zivanovic O, Carter J, Kauff ND, Barakat RR. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol. 2009. 115:504–509.
54. Hidaka T, Nakashima A, Shima T, Hasegawa T, Saito S. Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer. Obstet Gynecol Int. 2010. 2010:490219.
55. Hahn HS, Kim HJ, Yoon SG, Kim WC, Choi HJ, Kim HS, et al. Laparoscopy-assisted vaginal versus abdominal hysterectomy in endometrial cancer. Int J Gynecol Cancer. 2010. 20:102–109.
56. Santi A, Kuhn A, Gyr T, Eberhard M, Johann S, Gunthert AR, et al. Laparoscopy or laparotomy? A comparison of 240 patients with early-stage endometrial cancer. Surg Endosc. 2010. 24:939–943.
57. Holub Z, Bartos P, Jabor A, Eim J, Fischlova D, Kliment L. Laparoscopic surgery in obese women with endometrial cancer. J Am Assoc Gynecol Laparosc. 2000. 7:83–88.
58. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009. 27:5331–5336.
59. Ju W, Myung SK, Kim Y, Choi HJ, Kim SC. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2009. 19:400–406.
60. Chung HH, Kang SB, Cho JY, Kim JW, Park NH, Song YS, et al. Accuracy of MR imaging for the prediction of myometrial invasion of endometrial carcinoma. Gynecol Oncol. 2007. 104:654–659.
61. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 1987. 60:Suppl 8. 2035–2041.
62. Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998. 71:340–343.
63. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009. 373:125–136.
64. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010. 375:1165–1172.
65. Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ. Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother. 2009. 10:1939–1951.
66. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007. 25:2798–2803.
67. Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA. From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Ann Oncol. 2010. 21:1772–1778.
68. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009. 374:1331–1338.
69. Schwartz PE. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology (Williston Park). 2008. 22:1118–1125.
70. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol. 2002. 20:1248–1259.
71. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008. 26:83–89.
72. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006. 103:1070–1076.
73. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Metaanalysis of 21 studies. Ann Surg Oncol. 2009. 16:2315–2320.
74. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010. 34:433–443.
75. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009. 112:265–274.
76. Okamura H, Katabuchi H. Detailed morphology of human ovarian surface epithelium focusing on its metaplastic and neoplastic capability. Ital J Anat Embryol. 2001. 106:2 Suppl 2. 263–276.
77. Okamura H, Katabuchi H. Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis. Int Rev Cytol. 2005. 242:1–54.
78. Nitta M, Katabuchi H, Ohtake H, Tashiro H, Yamaizumi M, Okamura H. Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. Gynecol Oncol. 2001. 81:10–17.
79. Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T, et al. Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer. 2005. 93:116–123.
80. Sasaki R, Narisawa-Saito M, Yugawa T, Fujita M, Tashiro H, Katabuchi H, et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis. 2009. 30:423–431.
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles

Cited

Download

Close

Save citations to file

Download

Close

Email citations

Send Email
recaptcha 영역

Close

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr